<DOC>
	<DOCNO>NCT00418028</DOCNO>
	<brief_summary>Capecitabine active metastatic breast cancer conventional schedule ( 1250 mg/m2/12 hr 2 week , one week ) produce grade 2 great hand foot syndrome 50 % patient leading reduction . There theoretical reason administer S-phase specific agent continuous , protract rather intermittent schedule . The investigator study compare standard schedule ( 1250 mg/m2/12 hr 2 week , one week ) continuous administration schedule ( 800 mg/m2/12hr ) . The latter administer approximately cumulative dose capecitabine standard schedule . The study hypothesis grade 2 great hand foot syndrome reduce 50 % ( standard arm ) 20 % ( experimental arm ) . The investigator assume similar antitumor activity arm .</brief_summary>
	<brief_title>Standard Versus Continuous Capecitabine Advanced Breast Cancer</brief_title>
	<detailed_description>Capecitabine active metastatic breast cancer conventional schedule ( 1250 mg/m2/12 hr 2 week , one week ) produce grade 2 great hand foot syndrome 50 % patient leading reduction . Some author test continuous administration schedule capecitabine , show good tolerance apparently similar antitumor activity . Capecitabine pro-drug 5-FU mimic i.v . continuous infusion administration antimetabolite . On hand , theoretical reason administer S-phase specific agent continuous , protract rather intermittent schedule . Our study compare standard schedule ( 1250 mg/m2/12 hr 2 week , one week ) continuous administration schule ( 800 mg/m2/12hr ) . The latter schedule administer approximately cumulative dose capecitabine standard one . The study hypothesis grade 2 great hand foot syndrome reduce 50 % ( standard arm ) 20 % ( experimental arm ) . The investigator assume similar antitumor activity arm .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Inclusion Criteria 1 . Patients diagnose metastatic breast cancer 2 . Patients either receive previous treatment anthracyclines and/or taxanes ( either advance metastatic disease ) . 3 . The patient ambulatory functional ECOG &lt; 2 status ( see Appendix 2 ) . 4 . Patient present , least one lesion measurable accord RECIST criterion ( see Appendix 3 ) 5 . Patients life expectancy least 3 month . 6 . Patients agree able fulfill requirement whole protocol whole study . Exclusion criterion : 1 . Patients previously show unexpected severe reaction therapy fluoropyrimidines know sensitivity 5fluorouracile . 2 . Patients previously treat capecitabine . 3 . Patients organ transplant . 4 . Other disease severe affection : 1 . Patients previous convulsion , central nervous system diseases psychiatric disease , include dementia , investigator might consider clinically significant adversely affect therapeutic compliance . 2 . Patients severe intellectual impairment , unable carry basic daily routine establish depression . 3 . Clinical significant cardiac disease ( e. g. . congestive heart failure , symptomatic coronary artery disease cardiac arrhythmia fully control medication ) myocardial infarction within last 12 month . 4 . Severe renal impairment ( baseline creatinine clearance &lt; 30 ml/min ) 5 . Patients sign metastasis CNS . Patients history uncontrolled convulsion , central nervous system disorder psychiatric disability judge investigator clinically significant precluding inform consent interfere compliance oral drug intake exclude . 6 . Patients active infection . 7 . Patients history neoplasies previous five year , except basal cell skin cancer cervical cancer situ , cure . 8 . Patients show follow laboratory value : 1 . Neutrophil count &lt; 555 x 109/l 2 . Platelet count &lt; 100 x 109/l 3 . Serum creatinine &gt; 1,5 x límite superior de normalidad 4. seric bilirubin &gt; 2,0 x límite superior de normalidad 5 . ALAT , ASAT &gt; 2,5 x upper normality limit &gt; 5 x upper normality limit case liver metastases 6 . Alkaline phosphatase &gt; 2,5 x upper normality limit &gt; 5 x upper normality limit case liver metastases &gt; 10 x upper normality limit case bone metastasis . 9 . Patients radiotherapy four week prior initiation study treatment , previous radiotherapy marker lesion measure study ( new marker lesion appear previously irradiate area accept ) patient receive programmed radiotherapy . 10 . Patients major surgery within 4 week prior study treatment completely recover effect major surgery . 11 . Patients lack upper gastrointestinal tract physical integrity malabsorption syndrome . 12 . Patients receive two cycle chemotherapy metastatic disease . 13 . Patients Her2 + per FISH ó +++ Inmunohistochemistry</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>capecitabine</keyword>
	<keyword>schedule</keyword>
	<keyword>breast cancer</keyword>
</DOC>